Abstract
Cancer Immunology Immune checkpoint–inhibitor therapies bolster the antitumor activity of CD8+ T lymphocytes. Wang et al. performed single-cell analysis of tumor-infiltrating lymphocytes in mouse cancer models in which inhibitory anti–PD-1 (programmed cell death protein 1) and stimulatory anti–GITR (glucocorticoid-induced tumor necrosis factor receptor–related protein) antibodies together enhanced tumor control. This combination immunotherapy led to a synergistic increase in tumor antigen–specific memory precursor effector T cells dependent on the CD226 costimulatory pathway. Biochemical studies in liposomes identified CD226 as an additional target of dephosphorylation mediated by the PD-1–SHP2 (Src homology region 2) complex. Thus, further clinical trials could usefully test the efficacy of combined anti-GITR and anti–PD-1 immunotherapy in human cancer. Sci. Immunol. 3 , eaat7061 (2018).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
